Feedback / Questions
DA 3111 (trastuzumab biosimilar) - Meiji Seika, Dong-A
Meiji Seika Pharma: Annual Report 2013
(Meiji Seika)
-
Sep 26, 2013 -
Anticipated initiation of P1 trial for cancer in Q4 FY 2013 - H2 FY 2014
Anticipated new P1 trial • Anticipated trial completion date
•
Biosimilar • Oncology
http://www.meiji.com/english/investor/library/annualreport/2013/pdf/annualreport_2013_en_all_print.pdf
Sep 26, 2013
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.